home / stock / cspcy / cspcy quote
Last: | $3.02 |
---|---|
Change Percent: | -0.57% |
Open: | $3.0371 |
Close: | $3.02 |
High: | $3.0371 |
Low: | $3.018 |
Volume: | 6,197 |
Last Trade Date Time: | 07/17/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.02 | $3.0371 | $3.02 | $3.0371 | $3.018 | 6,197 | 07-17-2024 |
$3.02 | $3.015 | $3.02 | $3.035 | $3.0101 | 13,898 | 07-16-2024 |
$3.01 | $3.032 | $3.01 | $3.035 | $3.01 | 6,026 | 07-15-2024 |
$3.1 | $3.11 | $3.1 | $3.12 | $3.1 | 14,921 | 07-12-2024 |
$3.12 | $3.105 | $3.12 | $3.12 | $3.0801 | 7,266 | 07-11-2024 |
$3.03 | $3.14 | $3.03 | $3.14 | $3.03 | 18,326 | 07-10-2024 |
$3.06 | $3.0669 | $3.06 | $3.09 | $3.06 | 2,555 | 07-09-2024 |
$3.06 | $3.1 | $3.06 | $3.1 | $3.04 | 24,181 | 07-08-2024 |
$3.12 | $3.125 | $3.12 | $3.1397 | $3.12 | 8,080 | 07-05-2024 |
$3.15 | $3.15 | $3.15 | $3.152 | $3.15 | 8,276 | 07-04-2024 |
$3.15 | $3.15 | $3.15 | $3.152 | $3.15 | 8,276 | 07-03-2024 |
$3.15 | $3.15 | $3.15 | $3.17 | $3.15 | 9,051 | 07-02-2024 |
$3.125 | $3.16 | $3.125 | $3.176 | $3.12 | 13,372 | 07-01-2024 |
$3.11 | $3.136 | $3.11 | $3.14 | $3.11 | 17,028 | 06-28-2024 |
$3.16 | $3.185 | $3.16 | $3.185 | $3.16 | 14,618 | 06-27-2024 |
$3.275 | $3.25 | $3.275 | $3.29 | $3.25 | 21,559 | 06-26-2024 |
$3.16 | $3.175 | $3.16 | $3.18 | $3.15 | 19,777 | 06-25-2024 |
$3.198 | $3.195 | $3.198 | $3.214 | $3.1901 | 9,899 | 06-24-2024 |
$3.17 | $3.19 | $3.17 | $3.1997 | $3.17 | 19,367 | 06-21-2024 |
$3.22 | $3.22 | $3.22 | $3.23 | $3.215 | 3,205 | 06-20-2024 |
News, Short Squeeze, Breakout and More Instantly...
CSPC Pharmaceutical Group Ltd ADR Company Name:
CSPCY Stock Symbol:
OTCMKTS Market:
Elevation Oncology Highlights First-in-Human Phase 1 SYSA1801 (EO-3021) Clinical Data to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023 PR Newswire Initial data showed promising signs of efficacy, including a 47.1% ORR in patients with resistant/refract...
Elevation Oncology Highlights Clinical Data for SYSA1801 (EO-3021) to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023 PR Newswire NEW YORK , April 26, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology comp...
Corbus Pharmaceuticals expands oncology pipeline with the addition of a clinical stage Nectin-4 targeting Antibody Drug Conjugate (ADC) PR Newswire CRB-701 (SYS6002) is designed for improved therapeutic index and to act on a broad range of Nectin-4 expressing tumors ...